New insider activity at Pediatrix Medical Group ( (MD) ) has taken place on November 10, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Director Laura A Linynsky recently sold 10,000 shares of Pediatrix Medical Group stock, amounting to a total transaction value of $216,500.
Recent Updates on MD stock
Pediatrix Medical Group has seen recent positive developments that have led to increased price targets from analysts. Truist raised its price target due to the company’s Q3 earnings beat and guidance raise, reflecting strong financial performance. UBS also increased its price target, citing pricing growth and expectations of stable hospital administrative fees in 2026. The company’s Q3 revenue exceeded expectations, driven by reimbursement-related factors such as strong collection activity and higher patient acuity. Additionally, Pediatrix raised its FY25 adjusted EBITDA view, further supporting analyst optimism. These factors, coupled with strategic improvements and a favorable healthcare environment, have contributed to the positive outlook for Pediatrix Medical Group’s stock.
Spark’s Take on MD Stock
According to Spark, TipRanks’ AI Analyst, MD is a Outperform.
Pediatrix Medical Group’s overall score is driven by strong earnings performance and technical indicators, despite challenges in revenue growth and increased expenses. The stock’s valuation suggests it is attractively priced, contributing positively to the score.
To see Spark’s full report on MD stock, click here.
More about Pediatrix Medical Group
YTD Price Performance: 68.30%
Average Trading Volume: 833,519
Technical Sentiment Signal: Buy
Current Market Cap: $1.88B